Medical & Pharmaceutical Documentation Translation: An Overview

The stakes are different

Medical and pharmaceutical translation covers documents where a mistranslation could affect patient safety or regulatory approval — clinical trial protocols, informed consent forms, package inserts (bulas), and pharmacovigilance reports all require careful, domain-aware translation. An informed consent form is a particularly sensitive case: a patient enrolling in a clinical trial is meant to understand, in their own language, exactly what participation involves, and an imprecise translation can mean the consent obtained doesn't actually reflect informed understanding, which is a problem for the trial's ethical and regulatory standing, not just its paperwork. A clinical trial protocol carries a related risk in the other direction: a dosing instruction, an inclusion or exclusion criterion, or an adverse-event reporting threshold that is translated imprecisely can change what investigators at a trial site actually do, which is a different order of consequence than an awkward sentence in a business document.

Back-translation as a verification practice

For sensitive documents like informed consent forms, it is standard industry practice for a translation to be independently back-translated — translated back into the original source language by a different translator — and the two source versions compared for meaning drift. This isn't a certification STIB holds; it's a verification technique used across the pharmaceutical and clinical research industry specifically because consent language and safety information cannot rely on a single translator's judgment going unchecked. Where a client's protocol calls for back-translation, it fits naturally alongside the independent second-linguist review already built into a certified translation workflow, and the two checks catch different things: review against the source catches drift a single translator introduced, while back-translation surfaces a meaning that shifted in a way neither the original translator nor a reviewer working only in one direction would necessarily notice.

Regulatory context in Brazil

Companies submitting pharmaceutical documentation in Brazil typically work within ANVISA's regulatory framework; international submissions may also need to align with agencies like the FDA. Translators working on this content benefit from familiarity with the relevant regulatory terminology. A bula (package insert), for example, follows format and content conventions that ANVISA regulates specifically for the Brazilian market, distinct from a U.S. prescribing information sheet governed by FDA conventions — the underlying clinical facts may be identical, but the document structure, required warnings, and terminology expected by each regulator are not interchangeable, and a translation needs to respect the target regulator's conventions rather than mechanically mirroring the source document's format.

Confidentiality and patient data

Clinical and pharmacovigilance documents frequently contain identifiable patient information, which raises the stakes on confidentiality beyond what most business documents require. Brazil's LGPD (data protection law) governs how personal data, including health data, can be handled, and a translation workflow touching this kind of document needs controlled access and secure handling as a matter of course — the same discipline that a sponsor's own clinical operations and pharmacovigilance teams are required to apply internally. In practice that means limiting a document's circulation to the translators and reviewers actually assigned to the project, transferring files through channels appropriate to the sensitivity of the content, and treating a case report form or an adverse-event narrative with the same care a hospital or research site would apply to the original record.

Working with subject-matter translators

Medical and pharmaceutical documents benefit from translators with relevant subject-matter background, not just language fluency — terminology consistency across a large dossier is as important as any individual sentence. A pharmacovigilance report, a clinical study protocol, and its associated informed consent forms often need to use the same drug name, the same adverse-event terminology, and the same dosing language consistently across dozens or hundreds of pages submitted together, and a translator without the relevant clinical or regulatory background is more likely to introduce small inconsistencies that a reviewing regulator or ethics committee is trained to notice.

Dossiers that grow over time

A pharmacovigilance file or a clinical trial master file is rarely translated once and closed out — new adverse-event reports, protocol amendments, and updated safety information continue to arrive for as long as a product is on the market or a trial is active. Terminology decided on for the first submission needs to carry forward accurately into every later addition, sometimes years afterward, which means the glossary and reference materials built during an initial project have ongoing value and should be maintained rather than rebuilt from scratch each time new material comes in. This is one of the clearer cases where a documented terminology record pays for itself well beyond the first translated document.